Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.69 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 3/20 | 0.39 |
| ▸ | INMT | O95050 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.35 |
| ▸ | CYP21A2 | P08686 | 4/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11742221 | 1.00 | ADRA2A (0.69) | ADRA2AADRA2BADRA2CUSP2INMT | |
| SCHEMBL11742531 | 1.00 | ADRA2A (0.69) | ADRA2AADRA2BADRA2CUSP2INMT | |
| SCHEMBL7624477 | 0.98 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CUSP2INMT | |
| SCHEMBL5658841 | 0.88 | — | — | |
| SCHEMBL11738855 | 0.82 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CALDH1A1LMNA | |
| SCHEMBL15011277 | 0.78 | ADRA2A (0.64) | ADRA2AADRA2BADRA2CUSP2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL15006876 | 0.77 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CUSP2ALDH1A1 | |
| SCHEMBL11746021 | 0.75 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CUSP2ALDH1A1 | |
| SCHEMBL11742836 | 0.74 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CALDH1A1TSHR | |
| SCHEMBL27630439 | 0.71 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113816944-A | Anti-filovirus compounds and uses thereof | 中山大学 | 2021-12-21 | — | — | CN | disclosed |
| CN-111278825-A | Diazaspiro ROCK inhibitors | 百时美施贵宝公司 | 2020-06-12 | — | — | CN | disclosed |
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | disclosed |
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CADILLA HEALTHCARE LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CYP11B2, MAPT, CYP11B1 | ADRA2A 1460/4885ADRA2B 1068/4885ADRA2C 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.